Last reviewed · How we verify
Anti-CsbD Bovine IgG
Anti-CsbD bovine IgG is a passive immunotherapy that targets the CsbD protein, likely involved in bacterial pathogenesis or immune evasion.
Anti-CsbD bovine IgG is a passive immunotherapy that targets the CsbD protein, likely involved in bacterial pathogenesis or immune evasion. Used for Bacterial infection or disease associated with CsbD antigen expression (specific indication not publicly detailed).
At a glance
| Generic name | Anti-CsbD Bovine IgG |
|---|---|
| Also known as | Experimental |
| Sponsor | Johns Hopkins Bloomberg School of Public Health |
| Drug class | Monoclonal antibody (bovine-derived) |
| Target | CsbD protein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
This bovine immunoglobulin G antibody is designed to neutralize or block the CsbD antigen, which may be expressed by pathogenic bacteria or involved in disease pathogenesis. By binding to CsbD, the antibody aims to prevent bacterial virulence mechanisms or enhance immune clearance. The use of bovine-derived antibodies provides a source of polyclonal or monoclonal immunoglobulins for passive immunization.
Approved indications
- Bacterial infection or disease associated with CsbD antigen expression (specific indication not publicly detailed)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-CsbD Bovine IgG CI brief — competitive landscape report
- Anti-CsbD Bovine IgG updates RSS · CI watch RSS
- Johns Hopkins Bloomberg School of Public Health portfolio CI